Russian Covid-19 vaccine completes clinical trials at Sechenov University Center

Russia has become the first country to complete a clinical trial of a Covid-19 vaccine candidate in Russia, where the University of Sechinov said it has concluded its study.

The first group of 18 volunteers received the vaccine on 18 June, while the second group of 20 volunteers received the vaccine on 23 June at the Center for Practical Research for Interventional Cardiovascular Sciences, Sechenov University said earlier this month.

According to the report, Tarasov said that the first group of volunteers would be discharged on 15 July and the second group on 20 July.

According to researcher Elena Smolichoruk, head and head of the Sechenov University Center for Clinical Research on Medicine, the study’s data showed the vaccine candidate’s effectiveness, the Russian news agency TASS reported.

Smolarchuk was quoted by the news agency as saying: “The research is complete and it has been proven that the vaccine is safe. Volunteers will be discharged on 15 July and 20 July. ”

Trial participants will be monitored on an outpatient basis after being discharged.

Last month, Russia granted authorization for clinical trials of two formulations of the covid-19 vaccine candidate, developed by the Gemaleya National Research Center for Epidemiology and Microbiology.

Globally, COVID-19 has more than 12 million confirmed cases. More than 5.6 lakh people have died so far.

  • Russian scientists plan to launch world’s first COVID-19 vaccine next month
  • According to the Chief Researcher at Sechinov University, the test results showed that the vaccine is safe
  • To date, no vaccine has been approved for mass use without Phase III trials.

The Moscow Times reported that Gamale Center director Alexander Gintesburg told TASS that he expected the vaccine to be lodged in a ‘civil circulation’ on August 12-14.

Russia is one of several countries to develop a safe vaccine against COVID-19, which has so far claimed at least 569,879 lives and has infected approximately 12,992,640 people worldwide.

Start the Phase 3 trial of the COVID-19 vaccine in mid-August – what happens after the Phase-III trial?

Even after successful completion of Phase-III, it usually takes several months for a vaccine to be accessible to the general public. Multiple rounds of regulatory and administrative approval are required. This is why many scientists and even WHO officials maintain that it will take at least 12-18 months for any coronavirus vaccine to come on the market.

Nevertheless, the vaccine is unlikely to be available to all at once. Initially, it is expected to be available only to those who are at greater risk of getting an infection like a health worker. A universal vaccination against coronavirus can take years, as has happened with other vaccines.

Leave a Comment